Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Memorial Sloan-Kettering scientist wins Breakthrough Prize in Life Sciences

Charles L. Sawyers, Chair of Memorial Sloan-Kettering's Human Oncology and Pathogenesis Program (HOPP), was awarded the Breakthrough Prize in Life Sciences today. The award - established by Art Levinson, Sergey Brin, Anne Wojcicki, Mark Zuckerberg, Priscilla Chan, and Yuri Milner - recognizes "excellence in research aimed at curing intractable diseases and extending human life."

21 Feb 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

TIR-199 shows promise in fighting renal cancer

Chemists at the University of California, Riverside have developed a compound that holds much promise in the laboratory in fighting renal (kidney) cancer.

20 Feb 2013

Clonal evolution explains unpredictable leukemia disease course

Scientists have revealed the complicated clonal evolution of chronic lymphocytic leukemia, giving insight into the variation in disease course and its response to treatment.

19 Feb 2013

Researchers show how gene mutations shift and evolve over time in chronic lymphocytic leukemia

Tumors are not factories for the mass production of identical cancer cells, but are, in reality, patchworks of cells with different patterns of gene mutations. In a new study, researchers at Dana-Farber Cancer Institute and the Broad Institute show, more fully than ever before, how these mutations shift and evolve over time in chronic lymphocytic leukemia (CLL) - providing a strobe-like look at the genetic past, present, and future of CLL tumors.

15 Feb 2013

LLS, The Myeloproliferative Neoplasm Research Foundation issue MF Challenge Grant

In 2012, The Myeloproliferative Neoplasm (MPN) Research Foundation and The Leukemia & Lymphoma Society (LLS) jointly issued the MF Challenge Grant , seeking innovative approaches to reversing fibrosis in patients with myelofibrosis (MF).

15 Feb 2013

FOXC2 vital to epithelial-mesenchymal transition in breast cancer

Researchers have identified a pivotal protein in a cellular transformation that makes a cancer cell more resistant to treatment and more capable of growing and spreading, making it an inviting new target for drug development.

14 Feb 2013

Viewpoints: Obama prescription for Medicare is 'modest;' GOP doubts entitlement plan is serious

Somewhat more substantively, he called for a larger deficit-reduction deal built around loophole-closing tax reform and what he called "modest" reforms to Medicare and entitlements. In an apparent effort to rally Democrats to this cause, he called on "those of us who care deeply about programs like Medicare" to "embrace" reform.

14 Feb 2013

Tousled-like kinases play a key role in suppression and activation of herpesviruses

Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) hide within the worldwide human population. While dormant in the vast majority of those infected, these active herpesviruses can develop into several forms of cancer.

14 Feb 2013

Researchers investigate new avenue of treatment to help boost poor pancreatic cancer survival rates

Researchers at Georgia Regents University Cancer Center are investigating a new avenue of treatment to help boost poor pancreatic cancer survival rates.

13 Feb 2013

RNF20 protein required for MLL-rearranged leukemia amplification

Acute myeloid leukemia (AML) is an aggressive blood cancer that is currently incurable in 70% of patients. In a bold effort, CSHL scientists are among those identifying and characterizing the molecular mechanisms responsible for this cancer in order to generate potential new therapeutics.

12 Feb 2013

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

10 Feb 2013

Novel combination of ibrutinib and bortezomib could be effective new therapy for blood cancers

Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective new therapy for several forms of blood cancer, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).

7 Feb 2013

Seattle Genetics commences two SGN-CD19A phase I trials in hematologic malignancies

Seattle Genetics, Inc. today announced the initiation of two phase I clinical trials of SGN-CD19A, one for patients with B-cell acute lymphoblastic leukemia (ALL) and one for patients with B-cell non-Hodgkin lymphomas.

6 Feb 2013

Detection of B cells may predict graft-versus-host disease

The ability to detect B cells specific to the DEAD box protein may help predict the development of chronic graft-versus-host disease in male recipients of female hematopoietic cells, according to recent findings.

5 Feb 2013

Results from Merck’s Vorinostat phase 1 trial on lymphoma

Patients whose aggressive lymphomas have relapsed or failed to respond to the current front-line chemotherapy regimen now have an effective second line of attack against their disease.

5 Feb 2013

AIBioTech announces implementation of L-asparaginase activity assay for pediatric ALL

AIBioTech is pleased to announce implementation of a new laboratory derived test to measure L-asparaginase levels in patients being treated with any of the current asparaginase drugs including: Oncaspar, Kidrolase, Erwinaze, and Elspar.

5 Feb 2013

Hope against dangerous form of acute lymphoblastic leukemia

After an intensive three-year hunt through the genome, medical researchers have pinpointed mutations that leads to drug resistance and relapse in the most common type of childhood cancer-the first time anyone has linked the disease's reemergence to specific genetic anomalies.

4 Feb 2013

Scientists visualise molecular changes in Bax protein that force cells to die

Scientists at the Walter and Eliza Hall Institute have for the first time visualised the molecular changes in a critical cell death protein that force cells to die.

3 Feb 2013

Notch protein responsible for activating GATA2 gene to generate hematopoietic stem cells

Researchers from the group on stem cells and cancer at IMIM (Hospital del Mar Medical Research Institute) have deciphered one of the gene regulation circuits which would make it possible to generate hematopoietic blood cells, i.e. blood tissue stem cells.

1 Feb 2013

Leukemia News and Research

Further Reading

Memorial Sloan-Kettering scientist wins Breakthrough Prize in Life Sciences

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

TIR-199 shows promise in fighting renal cancer

Clonal evolution explains unpredictable leukemia disease course

Researchers show how gene mutations shift and evolve over time in chronic lymphocytic leukemia

LLS, The Myeloproliferative Neoplasm Research Foundation issue MF Challenge Grant

FOXC2 vital to epithelial-mesenchymal transition in breast cancer

Viewpoints: Obama prescription for Medicare is 'modest;' GOP doubts entitlement plan is serious

Tousled-like kinases play a key role in suppression and activation of herpesviruses

Researchers investigate new avenue of treatment to help boost poor pancreatic cancer survival rates

RNF20 protein required for MLL-rearranged leukemia amplification

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Novel combination of ibrutinib and bortezomib could be effective new therapy for blood cancers

Seattle Genetics commences two SGN-CD19A phase I trials in hematologic malignancies

Detection of B cells may predict graft-versus-host disease

Results from Merck’s Vorinostat phase 1 trial on lymphoma

AIBioTech announces implementation of L-asparaginase activity assay for pediatric ALL

Hope against dangerous form of acute lymphoblastic leukemia

Scientists visualise molecular changes in Bax protein that force cells to die

Notch protein responsible for activating GATA2 gene to generate hematopoietic stem cells

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News